TG Therapeutics (TGTX) Reports In-Line Q3 EPS, provides product guidance

TG Therapeutics (NASDAQ: TGTX) reported Q3 EPS of $0.02, in-line with the analyst estimate of $0.02. Revenue for the quarter came in at $83.3 million versus the consensus estimate of $81.21 million.

2024 Updated Target U.S. BRIUMVI Guidance

Raising BRIUMVI U.S. net product revenue target to $300 to $305 million for the full year 2024 (prior guidance of $290 to $300 million for full year 2024)

For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.

You May Also Be Interested In

• nCino Inc. (NCNO) PT Raised to $17 at JPMorgan
• Tractor Supply Company (TSCO) PT Lowered to $40 at DA Davidson as Recovery Appears Unlikely
• IQM joins HPE hybrid quantum-HPC platform collaboration